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Bronchial Thermoplasty: A New




Bronchial thermoplasty (BT) is a new endoscopic treatment approved by the
US Food and Drug Administration (FDA) in the management of severe refractory
asthma involving the delivery of controlled, therapeutic radiofrequency (RF)
energy to the airway wall. It is based on the premise of controlling bronchospasm
through a reduction of airway smooth muscle (ASM). Several clinical trials have
demonstrated improvements in asthma-related quality of life and a reduction in the
number of exacerbations following treatment with BT. However, several questions
remain regarding the use of BT, mechanism of action, selection of appropriate
patients, and long-term effects. Further studies are expected to elucidate the
underlying mechanisms that result in these improvements. This chapter discusses
key aspects of BT with a focus on the potential clinical effects of this promising
procedure. It also offers insight into the barriers to implementing a successful BT
program and strategies for overcoming them.
Keywords: severe asthma, bronchial thermoplasty, bronchoscopy,
airway smooth muscle
1. Introduction
Asthma is a common condition affecting more than 235 million people world-
wide [1]. Asthma is a chronic inflammatory disease characterized by variable air-
flow obstruction and bronchial hyperreactivity associated with airway remodeling.
Clinically, this manifests as recurrent episodes of wheezing, cough, dyspnea, and
chest tightness. Asthma treatment as of current standard is based on reducing
inflammation with inhaled corticosteroids (ICS) and relaxing airway smooth mus-
cle (ASM) with inhaled bronchodilators along with minimizing exposure to allergic
triggers [2]. While most patients achieve symptom control with these strategies,
there remains a significant cohort with severe asthma estimated at 5–10% who are
more difficult to treat. This group of severe asthmatics, however, is responsible for
a disproportionate share of the morbidity associated with the disease. The severe
asthma group is responsible for most of the asthma-related healthcare burden,
represented by the costs of hospitalizations, ER visits, physician office visits, and
use of medications [3–5]. This increased burden of severe asthma reflects the
inability of the existing treatment options to adequately control asthma in patients
with severe disease.
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Severe Asthma is defined by the American Thoracic Society and European
Respiratory Society as asthma requiring treatment with high-dose ICS and a second
controller medication (and/or systemic corticosteroids) to maintain asthma
control [6]. Unfortunately, therapeutic options for patients with severe asthma are
limited. Biologic therapy targeting IgE, IL-4 and IL-5 have been of particular
interest recently. In the past decade, new therapeutic approaches for asthma have
included the use of biological agents, such as omalizumab, a recombinant DNA-
derived humanized monoclonal antibody to IgE. However, in patients with severe
asthma with no indication for or those lacking a response to omalizumab, the new
targeted anti-IL-5 monoclonal antibodies including mepolizumab and reslizumab,
have been recently approved [7, 8]. However, they only appear effective in certain
subgroups of patients with asthma. Hence, new treatment strategies and approaches
are urgently needed for these patients. BT is a novel nonpharmacological therapy
which targets ASM in an effort to improve asthma control.
2. Airway smooth muscle in asthma
The airway smooth muscle (ASM) plays significant role in multiple normal
processes in the healthy airway, including control of bronchomotor tone,
immunomodulation, and extracellular matrix deposition. ASM cells in asthma
patients proliferate more rapidly than in non-asthmatic patients, resulting in an
increase in smooth muscle mass, with airway narrowing and loss of respiratory
function [9]. As a result, the proliferation and differentiation of mesenchymal cells
to myofibroblasts increases the deposition of extracellular matrix (ECM) and
smooth muscle cells [10]. All of the above modifications, in particular, ASM and
ECM deposition, increase the airway wall thickness, which correlates with severity
and duration of clinical episodes of asthma [11]. Bronchial remodeling, an increase
in ASM, has been shown to be related to clinical and functional severity of asthma
[9]. It has been shown that those with fatal asthma have an increased volume of
smooth muscle compared with nonfatal asthma [12].
These published findings led to the conclusion that smooth muscle cell alteration
is the fundamental structural change that distinguishes severe from moderate
asthma, and that phenotypic changes in ASM could contribute to reducing
control in subjects with severe asthma [13]. As a result, ASM has become
a therapeutic target.
3. Bronchial thermoplasty
BT is a nonpharmacological, novel endoscopic therapy that delivers controlled
RF thermal energy to the airway wall as part of a series of three bronchoscopic
procedures. It was approved by the US Food and Drug Administration for the
treatment of severe persistent asthma in patients aged over 18 years in 2010.It
involves application of RF thermal energy to the airways in asthma patients with the
goal of ablating the ASM. The first study of BT in human airways involved subjects
undergoing lobectomy for known or suspected lung cancer [14].
The current understanding is that BT can denature and destroy ASM and allows
the reduction of bronchospasm which in turn results in improved control of the
symptoms of severe asthma. Previous canine animal models have demonstrated that
BT causes almost complete destruction of ASM with moderate connective tissue
deposition when lung tissue has been examined histologically [15].
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Several clinical trials have demonstrated the long-term safety and effectiveness
of BT in terms of reducing exacerbations of asthma and improving patient quality
of life [16].
This chapter will summarize the information on mechanism of action,
procedure, efficacy, safety and patient selection, to better understand the path
forward for this promising technique.
4. Efficacy data in the short and long term: BT trials to real life
The first randomized clinical trial (RCT) evaluating the efficacy of BT was
conducted in 2006 by Cox et al. on 16 patients with stable mild-to-moderate asthma
[17]. In general, BT was well tolerated, with most of the procedure-related adverse
events occurring in the week following the procedure. Most of the events were
mild and transient and resolved spontaneously or required minor changes in
medications. There was a significant reduction in airway hyperresponsiveness as
reflected by increased PC20 (provocative concentration causing a 20% decline in
FEV1). In addition, there was a significant improvement in symptom-free days
(47 vs. 73%, P = 0.015) and peak expiratory flow rates measured at 12 weeks
following BT. Interestingly, there was no change in FEV1 during the 2 years of
follow-up. Chest CT was performed at 1 year and 2 years following BT did not
reveal any bronchiectasis or parenchymal lung disease [17].
Asthma Intervention Research (AIR) trial was the next major RCT in 2007. AIR
included 112 patients with moderate-to-severe asthma (FEV1 between 60 and 85%
of predicted) treated with BT [18]. Although, there were no differences in
prebronchodilator FEV1 percentage of predicted (72–74.3% vs. 75.8–75.7%,
P = 0.28) between patients who underwent BT and the control group when com-
pared to their pre-randomization baseline. There was, however, a significant
improvement in asthma symptoms as reflected by symptom-free days
(40.6  39.7% vs. 17.0  37.9%, P = 0.005), scores of the asthma control question-
naire (ACQ) (reduction, 1.2  1.0 vs. 0.5  1.0, P = 0.001) and asthma quality of
life questionnaire (AQLQ) (1.3  1.0 vs. 0.6  1.1, P = 0.003). Moreover, there was
a significant reduction in mild exacerbations of asthma and an increase in the
morning PEF, in patients treated with BT [18].
In 2007, the Research in Severe Asthma (RISA) designed to evaluate the safety
and efficacy of BT in patients with severe, symptomatic asthma was published [19].
This smaller trial included 32 patients (15 randomized to BT) with severe
persistent asthma as defined by uncontrolled symptoms despite high-dose ICS
and LABA use. Patients in BT arm showed a significant improvement in
pre-bronchodilator FEV1. The improvements in ACQ and AQLQ score persisted
despite the reduction of OCSs and bronchodilators.
These results were promising, however questions remained over the true
efficacy of BT versus potential placebo effect as the RISA and the AIR trials were
unblinded [19]. The AIR-2 trial was designed to answer these questions.
5. AIR-2 trial
The largest RCT, AIR2, was a double-blinded, randomized, sham-controlled
study included patients who had uncontrolled asthma despite high-dose ICS and a
LABA [20]. A total of 190 patients were treated with BT and 98 control patients
received sham thermoplasty. The procedure was performed by an unblinded
bronchoscopy team and all the assessments and follow-up visits were conducted by
3
Bronchial Thermoplasty: A New Therapeutic Option in Severe Uncontrolled Asthma
DOI: http://dx.doi.org/10.5772/intechopen.84466
a blinded team [20]. The primary outcome measure was to evaluate change from
baseline in average group mean Asthma Quality of Life Questionnaire (AQLQ)
score. In the BT group, a significantly greater proportion had a significant increase
in the AQLQ score compared with those who underwent sham bronchoscopy
(79 vs. 64%). There was also a meaningful reduction in the number of exacerbations
(32% risk reduction), emergency department visits (84% risk reduction) and days
lost from school/work (66% risk reduction) in those in the BT arm [20].
The results of these large RCTs are summarized in Table 1.
6. Long-term follow up and safety of BT
The earlier large clinical trials of BT showed marked improvements in asthma-
related quality of life and a reduction in the number of exacerbations and led to the
approval of the use of BT by the FDA in 2010 (Table 1). However, long-term safety
of BT was largely unaddressed, especially because of early concerns about thermal
tissue damage, possible subsequent risk of bronchial stenosis, and bronchomalacia
remained to be investigated. Recently, the results from the long-term follow-up of
patients enrolled in the AIR, RISA, and AIR-2 trials have provided some clarity in
this regard.
From the original study population of patients in the AIR trial, 45 patients
treated with BT and 24 control patients were followed for an additional 4 years
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Abbreviations: FEV1, forced expiratory volume in 1 sec; AQLQ, Asthma Quality of Life Questionnaire; ACQ,
Asthma Control Questionnaire; AIR, Asthma Intervention Research; RISA, Research in Severe Asthma.
Table 1.
Summary of clinical trials and long term follow up with BT in asthma.
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(5 years in total) and an additional 2 years (3 years in total) respectively [21]. In
comparison to the control subjects, patients who underwent BT had similar rates of
adverse respiratory events, oral corticosteroid bursts requirements, hospitaliza-
tions, and emergency department visits. Further, patients treated with BT contin-
ued to show improvements in airway hyperresponsiveness lasting up to 3 years,
suggesting the long-term efficacy of the procedure [21].
A long-term follow up of the patients with BT included in the RISA study,
performed for a total of 5 years, showed a significant decline in emergency visits
and hospitalizations for an exacerbation of asthma, and no further deterioration of
FEV1 [22].
Similarly, in the AIR-2 follow up study, patients were also monitored for another
4 years to evaluate the long-term effects of BT [23]. Patients treated with BT
showed a definite decrease in severe exacerbations of asthma and emergency hos-
pital visits [23]. Interestingly, a recent large retrospective study of patients with
persistent asthma suggests constant exacerbation frequency despite continued high-
intensity therapy with high doses of ICS and LABAs [24]. Therefore, long-term
comparative head to head safety studies for the use of BT in the treatment of asthma
are nevertheless required in future also.
7. Patient selection for bronchial thermoplasty
Currently, BT is approved for patients with uncontrolled severe persistent
asthma despite the use of an inhaled corticosteroid and LABA. As per the recent
Global Initiative for Asthma (GINA) guidelines, it has been suggested that “for
highly-selected adult patients with uncontrolled asthma despite use of
recommended therapeutic regimens and referral to an asthma specialty center, BT
is a potential treatment option” (Grade B evidence) [25]. In general, BT remains
contraindicated in patients with a pacemaker, internal defibrillator, or any
implantable electronic device [25].
Prior to consideration of BT, patients should undergo a focused evaluation to
ensure that the diagnosis of severe asthma is correct, treatment is optimized, and
comorbid conditions are treated. A thorough history and detailed physical exami-
nation constitute the next step. In addition, workup as necessary to exclude an
alternative diagnosis, such as sarcoidosis, cystic fibrosis (CF), other non-CF
bronchiectatic lung disease, alpha-1 antitrypsin deficiency, and chronic obstructive
pulmonary disease (COPD) should also be carried out [26]. In general, full pulmo-
nary function testing as well as a high-resolution CT scan of the lungs is also
desirable. Before labeling it as severe asthma, the inhaler technique and adherence
are also evaluated rigorously, as corrective interventions have shown to improve
asthma control [27].
8. BT procedure
BT is based on the principle of endobronchial controlled delivery of RF thermal
energy to modify the structure of the airway wall thereby reducing the amount of
ASM with a device called the Alair BT System (Boston Scientific, Marlborough, MA,
USA). A bronchoscope with a disposable catheter with a diameter of 2.0 mm in the
operating channel is used to obtain better visualization and complete treatment of
subsegmental bronchi [17]. The distal tip of the catheter has an expandable four-
electrode basket, through which 65°C radio frequencies are delivered in order to
visible bronchial areas sequentially [17]. The correct order involves the right lower
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lobe (first session) then left lower lobe (second session), followed by both upper
lobes (third session). The right middle lobe is generally not treated because of the
remote possibility of obstruction and right middle lobe syndrome. A typical BT
session lasts about 30–45 min.
The entire visible length of each bronchus is treated with each pulse targeting
a 5 mm section of bronchus between 3 and 10 mm in diameter, starting at the
periphery and moving proximally. On an average the full treatment consists of
30–70 activations per lobe, up to 44 for the right lower lobe, 47 for the left lower
lobe and 60 for the upper lobes [21]. Successful BT comprises three procedures
performed at 20 day intervals [17]. Mild bronchoconstriction, mucous
hypersecretion, and minor bleeding related to superficial trauma are the most
commonly encountered complications. Patients are given systemic corticosteroids
and nebulized. Bronchodilators prior and after the procedure to minimize the com-
plications in the post procedure setting.
BT should be performed by an experienced bronchoscopist in an adequate set-
ting with appropriate clinical monitoring and the facility and expertise to address
any potential post-intervention complications. Mayse et al. has described the
appropriate assessment and monitoring of the patient before, during and after the
procedure [28].
9. What are the current guidelines regarding bronchial thermoplasty?
As per the current European Respiratory Society and American Thoracic Society
(ERS/ATS) guidelines BT is recommended in adults with severe refractory asthma,
despite optimal therapy, in the context of an institutional review board-approved
independent systematic registry, or for use in a clinical study only [29]. A recent
Cochrane Database systematic review also has the same recommendation and high-
lights the need for further studies on BT to determine the mechanisms of action in
patients with different phenotypes of asthma [30]. Interestingly the BT Global
Registry, a 2 year observational study is expected to provide new and valuable data
on BT, is currently recruiting patients [31].
10. Pharmacoeconomics of bronchial thermoplasty
BT is an expensive procedure, but recent studies have shown that the obvious
high cost may be at least partially balanced by the reduction in costs due to decrease
in acute exacerbations of asthma requiring emergency department visits and the
effects of improved quality of life for patients [32]. A subsequent study has con-
firmed that BT has a 60% chance to be more cost effective as compared with
omalizumab and standard therapy on the willingness-to pay of $100,000/quality-
adjusted life year [33]. Zein and colleagues also concluded that BT is a cost effective
intervention in patients with asthma at high risk of exacerbations [34]. However,
a study carried out in Singapore found that BT is not cost effective compared with
optimized asthma therapy unless the cost of the procedure is decreased so as to
make it more cost effective [35].
11. Conclusions
BT is the only FDA approved nonpharmacological treatment available for severe
asthma patients. In contrast to therapies for asthma targeting the underlying
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inflammatory response, BT specifically targets the ASM. Recent clinical trials have
established its safety, ability to improve quality of life and reduction in exacerba-
tions in patients with severe asthma. However, the exact mechanisms that underlie
these improvements seen with BT remain at best still poorly understood. Future
studies on the mechanism of action of BT, including phenotyping of patients and
treatment approaches in identifying the patients most likely to respond to this
therapy are expected to solve the existing conundrum.
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